BackgroundThe relationship of 5-aminosalicylates' use with the risk of colorectal neoplasia in patients with inflammatory bowel disease (IBD) has been the focus of a growing body of research. AimTo investigate this association through an updated meta-analysis of observational studies. MethodsPubMed, Scopus and major conference proceedings were searched up to December 2016. The identified studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates were calculated using random-effect models. Detailed subgroup analyses were performed. The GRADE approach was used to assess the quality of evidence. ResultsThirty-one independent observational studies including 2137 cases of colorectal neoplasia (of which 76% were cancers) were incorporated. Between-study heterogeneity was moderate, while strong suspicion of small-study effects was raised. The overall analysis revealed a protective association between 5-aminosalicylates' use and colorectal neoplasia (RR=0.57, 95% CI: 0.45-0.71). When the analysis was stratified according to study design and setting, the association was significant in cohort (RR=0.65, 95% CI: 0.43-0.99 n=10) and case-control studies (RR=0.53, 95% CI: 0.40-0.70 n=21), population-based (RR=0.70, 95% CI: 0.52-0.94 n=12) and hospital-based studies (RR=0.46, 95% CI: 0.34-0.61 n=19). Exposure to 5-aminosalicylates was protective against cancer (RR=0.58, 95% CI: 0.45-0.74) and dysplasia (RR=0.54, 95% CI: 0.35-0.84). The reduction in colorectal neoplasia risk was strong in ulcerative colitis (RR=0.50, 95% CI: 0.38-0.64), but nonsignificant in Crohn's disease (RR=0.76, 95% CI: 0.43-1.33). Mesalazine (mesalamine) use was protective (RR=0.70, 95% CI: 0.51-0.94) with evidence of a dose-effect. The effect of sulfasalazine was marginally nonsignificant (RR=0.72, 95% CI: 0.51-1.01). ConclusionsOur findings support a potential chemopreventive role of 5-aminosalicylates in IBD. Further, high-quality prospective research is warranted.
Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease
Bonovas S;Fiorino G;Danese S
2017-01-01
Abstract
BackgroundThe relationship of 5-aminosalicylates' use with the risk of colorectal neoplasia in patients with inflammatory bowel disease (IBD) has been the focus of a growing body of research. AimTo investigate this association through an updated meta-analysis of observational studies. MethodsPubMed, Scopus and major conference proceedings were searched up to December 2016. The identified studies were evaluated for publication bias and heterogeneity. Pooled relative risk (RR) estimates were calculated using random-effect models. Detailed subgroup analyses were performed. The GRADE approach was used to assess the quality of evidence. ResultsThirty-one independent observational studies including 2137 cases of colorectal neoplasia (of which 76% were cancers) were incorporated. Between-study heterogeneity was moderate, while strong suspicion of small-study effects was raised. The overall analysis revealed a protective association between 5-aminosalicylates' use and colorectal neoplasia (RR=0.57, 95% CI: 0.45-0.71). When the analysis was stratified according to study design and setting, the association was significant in cohort (RR=0.65, 95% CI: 0.43-0.99 n=10) and case-control studies (RR=0.53, 95% CI: 0.40-0.70 n=21), population-based (RR=0.70, 95% CI: 0.52-0.94 n=12) and hospital-based studies (RR=0.46, 95% CI: 0.34-0.61 n=19). Exposure to 5-aminosalicylates was protective against cancer (RR=0.58, 95% CI: 0.45-0.74) and dysplasia (RR=0.54, 95% CI: 0.35-0.84). The reduction in colorectal neoplasia risk was strong in ulcerative colitis (RR=0.50, 95% CI: 0.38-0.64), but nonsignificant in Crohn's disease (RR=0.76, 95% CI: 0.43-1.33). Mesalazine (mesalamine) use was protective (RR=0.70, 95% CI: 0.51-0.94) with evidence of a dose-effect. The effect of sulfasalazine was marginally nonsignificant (RR=0.72, 95% CI: 0.51-1.01). ConclusionsOur findings support a potential chemopreventive role of 5-aminosalicylates in IBD. Further, high-quality prospective research is warranted.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
